The TNF-α inhibitor etanercept and the IL-1 receptor antagonist anakinra markedly suppress NF-κB activation and have been successfully used in patients with lupus nephritis caused by TNFAIP3 mutations [60, 61]. Here, NFKB1 is linked to lupus nephritis.